Exelixis, Inc. (NASDAQ:EXEL) came in focus in November-2010 on news that Phase II clinical trial data on XL184 in ovarian and prostate cancer showed that the drug appears to be a help in both tumor types after it was effectively given back rights to the drug by Bristol-Myers Squibb earlier. Shares are trading at $8 above the average analyst target of $7.75. If positive results keep coming, EXEL may gain more but with no news, it will drop.

AMLN-Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN)

Amylin Pharmaceuticals, Inc. (NASDAQ:AMLN) has dropped a lot from its highs but is still valued higher than its average target of $13.2. The company is looking for an expanded approval for its BYETTA along with Basal insulin for diabetes but looks like even the approval may not be enough to justify this price.

ILMN- Illumina, Inc. (NASDAQ: ILMN)

Illumina, Inc. (NASDAQ:ILMN) has almost doubled this year from its 52 week low of $32. It is now trading right near average analyst predictions of $64. Morgan Stanley has just raised the target price for ILMN to $78. This can go either way from here. A good earning report will take it near to Morgan Stanley's target or else it will see deep red.

OSIR- Osiris Therapeutics, Inc. (NASDAQ: OSIR)
Osiris Therapeutics, Inc. (NASDAQ:OSIR) is known for its extremely low volume trade. It is trading at $7.45 which is much above the average analyst estimate of $5.88. Either the analysts are missing something or OSIR is gaining on paid promotions. OSIR had a huge drop in September last year and since then it has stayed sluggish. Further news may give it direction but for now it is going nowhere.